Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1997 1
2001 2
2002 3
2003 1
2004 6
2005 6
2006 11
2007 4
2008 12
2009 12
2010 2
2011 16
2012 10
2013 8
2014 4
2015 10
2016 10
2017 20
2018 9
2019 8
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

156 results
Results by year
Filters applied: . Clear all
Page 1
Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.
Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, Martin FP, Cominetti O, Welsh C, Rieder A, Traynor J, Gregory C, De Palma G, Pigrau M, Ford AC, Macri J, Berger B, Bergonzelli G, Surette MG, Collins SM, Moayyedi P, Bercik P. Pinto-Sanchez MI, et al. Gastroenterology. 2017 Aug;153(2):448-459.e8. doi: 10.1053/j.gastro.2017.05.003. Epub 2017 May 5. Gastroenterology. 2017. PMID: 28483500 Free article. Clinical Trial.
BACKGROUND & AIMS: Probiotics can reduce symptoms of irritable bowel syndrome (IBS), but little is known about their effects on psychiatric comorbidities. ...
BACKGROUND & AIMS: Probiotics can reduce symptoms of irritable bowel syndrome (IBS), but little is known about thei …
Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis.
Yuan F, Ni H, Asche CV, Kim M, Walayat S, Ren J. Yuan F, et al. Curr Med Res Opin. 2017 Jul;33(7):1191-1197. doi: 10.1080/03007995.2017.1292230. Epub 2017 Mar 7. Curr Med Res Opin. 2017. PMID: 28166427 Review.
BACKGROUND: The treatment of irritable bowel syndrome (IBS) is a challenge because its cause remains unknown. Previous clinical trials to examine the efficacy of probiotic Bifidobacterium infantis 35624 (B. infantis) in patients with IBS have shown inconsiste …
BACKGROUND: The treatment of irritable bowel syndrome (IBS) is a challenge because its cause remains unknown. Previous …
A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.
Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K. Staudacher HM, et al. Gastroenterology. 2017 Oct;153(4):936-947. doi: 10.1053/j.gastro.2017.06.010. Epub 2017 Jun 15. Gastroenterology. 2017. PMID: 28625832 Clinical Trial.
BACKGROUND & AIMS: Dietary restriction of fermentable carbohydrates (a low FODMAP diet) has been reported to reduce symptoms in some patients with irritable bowel syndrome (IBS). ...
BACKGROUND & AIMS: Dietary restriction of fermentable carbohydrates (a low FODMAP diet) has been reported to reduce symptoms in some pat …
Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review.
Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Pittayanon R, et al. Gastroenterology. 2019 Jul;157(1):97-108. doi: 10.1053/j.gastro.2019.03.049. Epub 2019 Mar 30. Gastroenterology. 2019. PMID: 30940523
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is common but difficult to treat. Altering the gut microbiota has been proposed as a strategy for treatment of IBS, but the association between the gut microbiome and IBS symptoms has not been well establi …
BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is common but difficult to treat. Altering the gut microbiota has …
Mental health: thinking from the gut.
Schmidt C. Schmidt C. Nature. 2015 Feb 26;518(7540):S12-5. doi: 10.1038/518S13a. Nature. 2015. PMID: 25715275 No abstract available.
When the low FODMAP diet does not work.
Halmos EP. Halmos EP. J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:69-72. doi: 10.1111/jgh.13701. J Gastroenterol Hepatol. 2017. PMID: 28244666 Review.
Irritable bowel syndrome (IBS) is heterogeneous. Patients need proper assessment and explanation of IBS pathophysiology and appropriate therapies. ...
Irritable bowel syndrome (IBS) is heterogeneous. Patients need proper assessment and explanation of IBS pathophysiology
Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota.
Jin Y, Ren X, Li G, Li Y, Zhang L, Wang H, Qian W, Hou X. Jin Y, et al. J Gastroenterol Hepatol. 2018 Feb;33(2):443-452. doi: 10.1111/jgh.13841. J Gastroenterol Hepatol. 2018. PMID: 28573746
BACKGROUND AND AIMS: Rifaximin is a minimally absorbed antibiotic, which has shown efficacy in irritable bowel syndrome (IBS) patients. ...
BACKGROUND AND AIMS: Rifaximin is a minimally absorbed antibiotic, which has shown efficacy in irritable bowel syndrome
Bifidobacteria and Their Health-Promoting Effects.
Hidalgo-Cantabrana C, Delgado S, Ruiz L, Ruas-Madiedo P, Sánchez B, Margolles A. Hidalgo-Cantabrana C, et al. Microbiol Spectr. 2017 Jun;5(3). doi: 10.1128/microbiolspec.BAD-0010-2016. Microbiol Spectr. 2017. PMID: 28643627 Review.
The genus Bifidobacterium belongs to the Actinobacteria phylum. Firmicutes, Bacteroidetes, and Actinobacteria constitute the most abundant phyla in the human intestinal microbiota, Firmicutes and Bacteroidetes being predominant in adults, and Actinobacteria i …
The genus Bifidobacterium belongs to the Actinobacteria phylum. Firmicutes, Bacteroidetes, and Actinobacteria constitute the m …
Alterations of gut microbiota in patients with irritable bowel syndrome: A systematic review and meta-analysis.
Zhuang X, Xiong L, Li L, Li M, Chen M. Zhuang X, et al. J Gastroenterol Hepatol. 2017 Jan;32(1):28-38. doi: 10.1111/jgh.13471. J Gastroenterol Hepatol. 2017. PMID: 27300149 Review.
BACKGROUND AND AIMS: Alterations of gut microbiota were assumed to be the etiology and pathogenesis of irritable bowel syndrome (IBS) in some studies. ...
BACKGROUND AND AIMS: Alterations of gut microbiota were assumed to be the etiology and pathogenesis of irritable bowel synd
Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial.
Baştürk A, Artan R, Yılmaz A. Baştürk A, et al. Turk J Gastroenterol. 2016 Sep;27(5):439-443. doi: 10.5152/tjg.2016.16301. Turk J Gastroenterol. 2016. PMID: 27782892 Free article. Clinical Trial.
BACKGROUND/AIMS: Irritable bowel syndrome (IBS) is an important health problem that presents serious social burdens and high costs. ...
BACKGROUND/AIMS: Irritable bowel syndrome (IBS) is an important health problem that presents serious social burdens and …
156 results
Jump to page
Feedback